Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
Myeloid sarcoma (MS) is a rare extramedullary blast proliferation of immature cells of myeloid origin. It is commonly associated with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN), and may precede, coincide with, or follow the diagnosis of a myelo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048921000534 |
| _version_ | 1818524077802913792 |
|---|---|
| author | Nikeeta Mandhan Farah Yassine Ke Li Talha Badar |
| author_facet | Nikeeta Mandhan Farah Yassine Ke Li Talha Badar |
| author_sort | Nikeeta Mandhan |
| collection | DOAJ |
| description | Myeloid sarcoma (MS) is a rare extramedullary blast proliferation of immature cells of myeloid origin. It is commonly associated with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN), and may precede, coincide with, or follow the diagnosis of a myeloid disorder. MS treatment is controversial, but AML induction like regimens is usually recommended. We present an unusual case of de novo TP53 mutated MDS/MPN overlap with bladder MS. Due to the high-risk nature of the disease, the patient was induced with decitabine and venetoclax combination therapy, resulting in complete remission. The response was further consolidated by an allogeneic hematopoietic stem cell transplantation. |
| first_indexed | 2024-12-11T05:52:44Z |
| format | Article |
| id | doaj.art-42fbf58f64d94eaf86b772c3a573aa46 |
| institution | Directory Open Access Journal |
| issn | 2213-0489 |
| language | English |
| last_indexed | 2024-12-11T05:52:44Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj.art-42fbf58f64d94eaf86b772c3a573aa462022-12-22T01:18:46ZengElsevierLeukemia Research Reports2213-04892022-01-0117100286Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimenNikeeta Mandhan0Farah Yassine1Ke Li2Talha Badar3Dow Medical College, Karachi City, Sindh, PakistanDivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, United States of AmericaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Florida, United States of AmericaDivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, United States of America; Corresponding author at: Assistant Professor of Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, United States of America.Myeloid sarcoma (MS) is a rare extramedullary blast proliferation of immature cells of myeloid origin. It is commonly associated with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN), and may precede, coincide with, or follow the diagnosis of a myeloid disorder. MS treatment is controversial, but AML induction like regimens is usually recommended. We present an unusual case of de novo TP53 mutated MDS/MPN overlap with bladder MS. Due to the high-risk nature of the disease, the patient was induced with decitabine and venetoclax combination therapy, resulting in complete remission. The response was further consolidated by an allogeneic hematopoietic stem cell transplantation.http://www.sciencedirect.com/science/article/pii/S2213048921000534Myeloid sarcomaMDS/MPN overlapTP53 mutationDecitabine-venetoclaxHematopoietic stem cell transplantation |
| spellingShingle | Nikeeta Mandhan Farah Yassine Ke Li Talha Badar Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen Leukemia Research Reports Myeloid sarcoma MDS/MPN overlap TP53 mutation Decitabine-venetoclax Hematopoietic stem cell transplantation |
| title | Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen |
| title_full | Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen |
| title_fullStr | Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen |
| title_full_unstemmed | Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen |
| title_short | Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen |
| title_sort | bladder myeloid sarcoma with tp53 mutated myelodysplastic syndrome myeloproliferative neoplasm overlap syndrome response to decitabine venetoclax regimen |
| topic | Myeloid sarcoma MDS/MPN overlap TP53 mutation Decitabine-venetoclax Hematopoietic stem cell transplantation |
| url | http://www.sciencedirect.com/science/article/pii/S2213048921000534 |
| work_keys_str_mv | AT nikeetamandhan bladdermyeloidsarcomawithtp53mutatedmyelodysplasticsyndromemyeloproliferativeneoplasmoverlapsyndromeresponsetodecitabinevenetoclaxregimen AT farahyassine bladdermyeloidsarcomawithtp53mutatedmyelodysplasticsyndromemyeloproliferativeneoplasmoverlapsyndromeresponsetodecitabinevenetoclaxregimen AT keli bladdermyeloidsarcomawithtp53mutatedmyelodysplasticsyndromemyeloproliferativeneoplasmoverlapsyndromeresponsetodecitabinevenetoclaxregimen AT talhabadar bladdermyeloidsarcomawithtp53mutatedmyelodysplasticsyndromemyeloproliferativeneoplasmoverlapsyndromeresponsetodecitabinevenetoclaxregimen |